Exploring the mechanism of Tetrastigma hemsleyanum in treating viral meningitis based on network pharmacology and molecular docking technology. Active ingredients of T. hemsleyanum were collected from the China National Knowledge Infrastructure （CNKI） and PubMed databases. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP） was utilized to search for these active ingredients and identify their corresponding targets. Therapeutic targets for viral meningitis were obtained from the Online Mendelian Inheritance in Man （OMIM）， DisGeNET， and GeneCards databases. Cytoscape software was employed to construct a “drug - component - target - disease” network and a “component - target - pathway” network. Gene Ontology （GO） functional enrichment and kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analyses were performed using R language. A total of 12 major active components and 181 potential targets were screened from T. hemsleyanum. By intersecting these with 796 viral meningitis - related targets， 86 common drug - disease targets were identified. The protein - protein interaction （PPI） network highlighted key target proteins such as tumor protein 53 （TP53），interleukin - 6 （IL-6）， AKT serine/threonine kinase 1 （AKT1）， jun proto - oncogene （JUN）， and interleukin - 1 Beta （IL-1β）. KEGG enrichment analysis revealed significant pathways， including the AGE - RAGE signaling pathway， hepatitis B， TNF signaling pathway， and human cytomegalovirus infection. Therefore， T. hemsleyanum may exert its potential therapeutic effects against viral meningitis through a multi - component， multi - target， and multi - pathway mechanism.